In vitro activities of tigecycline against erythromycin-resistant Streptococcus pyogenes and Streptococcus agalactiae:: Mechanisms of macrolide and tetracycline resistance

被引：39

作者：

Betriu, C ^{[1
]}

Culebras, E ^{[1
]}

Rodríguez-Avial, I ^{[1
]}

Gómez, M ^{[1
]}

Sánchez, BA ^{[1
]}

Picazo, JJ ^{[1
]}

机构：

[1] Hosp Clin San Carlos, Dept Clin Microbiol, Madrid 28040, Spain

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2004年 / 48卷 / 01期

关键词：

D O I：

10.1128/AAC.48.1.323-325.2004

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The activity of tigecycline was tested against erythromycin-resistant streptococci (107 Streptococcus pyogenes and 98 Streptococcus agalactiae strains). The presence of erythromycin and tetracycline resistance genes was determined by PCR. Among S. pyogenes strains the most prevalent gene was mef(A) (91.6%). The erm (B) gene was the most prevalent (65.3%) among S. agalactiae strains. Tigecycline proved to be very active against all the isolates tested (MIC at which 90% of the isolates tested were inhibited, 0.06 mug/ml), including those resistant to tetracycline.

引用

页码：323 / 325

页数：3

共 19 条

[1] In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain
Betriu, C
Rodríguez-Avial, I
Sánchez, BA
Gómez, M
Alvarez, J
Picazo, JJ
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) : 892 - 895
[2] Incidence of erythromycin resistance in Streptococcus pyogenes:: A 10-year study
Betriu, C
Casado, MC
Gómez, M
Sanchez, A
Palau, ML
Picazo, JJ
[J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1999, 33 (04) : 255 - 260
[3] Erythromycin and clindamycin resistance and telithromycin susceptibility in Streptococcus agalactiae
Betriu, C
Culebras, E
Gómez, M
Rodríguez-Avial, I
Sánchez, BA
Agreda, MC
Picazo, JJ
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (03) : 1112 - 1114
[4] Prevalence of macrolide and tetracycline resistance mechanisms in Streptococcus pyogenes isolates and in vitro susceptibility to telithromycin
Betriu, C
Culebras, E
Redondo, M
Rodríguez-Avial, I
Gómez, M
Boloix, A
Picazo, JJ
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (03) : 436 - U11
[5] Cornwell TB, 1998, J ADVERTISING, V27, P1
[6] Prevalence and mechanisms of macrolide resistance in clinical isolates of group A streptococci from Ontario, Canada
De Azavedo, JCS
Yeung, RH
Bast, DJ
Duncan, CL
Borgia, SB
Low, DE
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (09) : 2144 - 2147
[7] GAR-936 (9-t-butylglycylamido-minocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae:: preliminary guidelines and interpretive criteria
Deshpande, LM
Gales, AC
Jones, RN
[J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2001, 18 (01) : 29 - 35
[8] Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates
Gales, AC
Jones, RN
[J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 36 (01) : 19 - 36
[9] Different erythromycin resistance mechanisms in group C and group G streptococci
Kataja, J
Seppälä, H
Skurnik, M
Sarkkinen, H
Huovinen, P
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (06) : 1493 - 1494
[10] Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates
Milatovic, D
Schmitz, FJ
Verhoef, J
Fluit, AC
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (01) : 400 - 404

← 1 2 →